Trevi Therapeutics Inc. has released its financial results for the first quarter of 2025, reporting a net loss of $10.3 million compared to a net loss of $10.9 million during the same period in 2024. General and administrative expenses increased to $3.7 million from $3.1 million in the previous year, primarily due to higher personnel-related costs. Research and development expenses decreased to $7.8 million from $8.8 million in 2024, attributed to reduced clinical development expenses for the Human Abuse Potential study, which was actively enrolling patients in the prior year. The company ended the quarter with $103.3 million in cash, cash equivalents, and marketable securities, with an expected cash runway extending into the fourth quarter of 2026. Significant business updates include the completion of patient enrollment and the last patient visit in the Phase 2b CORAL trial for chronic cough in idiopathic pulmonary fibrosis $(IPF.UK)$ patients, with topline results anticipated in the second quarter of 2025. Additionally, Trevi announced positive topline results from the Phase 2a RIVER trial in patients with refractory chronic cough, achieving statistically significant reductions in 24-hour cough frequency and other secondary endpoints. The company is now reviewing the full data set and designing the next planned trial for Haduvio in refractory chronic cough patients.